Global Chronic Kidney Disease Medication Market Growth (Status and Outlook) 2024-2030

Global Chronic Kidney Disease Medication Market Growth (Status and Outlook) 2024-2030

Chronic Kidney Disease (CKD) Medication refers to a class of drugs specifically designed to manage and treat the progression of chronic kidney disease, a long-term condition characterized by the gradual loss of kidney function. These medications address various aspects of CKD, such as controlling blood pressure, managing blood sugar levels, correcting electrolyte imbalances, and treating complications like anemia and bone disease. The primary goal of CKD medications is to slow down kidney damage, alleviate symptoms, and improve the patient's quality of life.

The global Chronic Kidney Disease Medication market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “Chronic Kidney Disease Medication Industry Forecast” looks at past sales and reviews total world Chronic Kidney Disease Medication sales in 2022, providing a comprehensive analysis by region and market sector of projected Chronic Kidney Disease Medication sales for 2023 through 2029. With Chronic Kidney Disease Medication sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Chronic Kidney Disease Medication industry.

This Insight Report provides a comprehensive analysis of the global Chronic Kidney Disease Medication landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Chronic Kidney Disease Medication portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Chronic Kidney Disease Medication market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Chronic Kidney Disease Medication and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Chronic Kidney Disease Medication.

United States market for Chronic Kidney Disease Medication is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Chronic Kidney Disease Medication is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Chronic Kidney Disease Medication is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Chronic Kidney Disease Medication players cover Amgen, Roche, FibroGen, AstraZeneca, GlaxoSmithKline, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Chronic Kidney Disease Medication market by product type, application, key players and key regions and countries.

Segmentation by Type:
Angiotensin-Converting Enzyme (ACE) Inhibitors
Angiotensin II Receptor Blockers (ARBs)
Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors
Others

Segmentation by Application:
Hospital
Specialist Clinic

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Angiotensin-Converting Enzyme (ACE) Inhibitors
Angiotensin II Receptor Blockers (ARBs)
Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors
Others

Segmentation by Application:
Hospital
Specialist Clinic

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Amgen
Roche
FibroGen
AstraZeneca
GlaxoSmithKline
Akebia Therapeutics
Kissei
Teva Pharmaceutical Industries
Pfizer
Sanofi
Novartis

Please note: The report will take approximately 2 business days to prepare and deliver.